Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aldeyra Therapeu (NQ: ALDX )

10.52 USD +0.08 (+0.77%)
Streaming Delayed Price Updated: 9:43 AM EDT, Apr 23, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Aldeyra Therapeu

< Previous 1 2 3 4 5 6 7 8 Next >
Aldeyra Therapeutics Releases Expanded Results from Allergen Chamber Trial and Announces Plans to Initiate the Phase 3 INVIGORATE Trial in Patients with Allergic Conjunctivitis
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated... 
From Business Wire News Releases
Aldeyra Therapeutics to Host Conference Call and Webcast to Release Expanded Results from Allergen Chamber Trial and Announce Design of Phase 3 INVIGORATE Trial in Patients with Allergic Conjunctiviti
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call and webcast at 8:00 a.m. ET Thursday, October 31, 2019 to release expanded results from its allergen chamber clinical... 
From Business Wire News Releases
ZAGENO Appoints Josef H. von Rickenbach as Chairman of its Board of Directors
From GlobeNewswire News Releases
Aldeyra Therapeutics to Present at Ophthalmology Innovation Summit at American Academy of Ophthalmology 2019 Annual Meeting
Aldeyra Therapeutics will discuss its Phase 3 ocular programs on Thursday, October 10 at the Ophthalmology Innovation Summit in San Francisco. 
From Business Wire News Releases
Aldeyra Therapeutics to Present Phase 3 ALLEVIATE Trial Results in Allergic Conjunctivitis at American Academy of Ophthalmology 2019 Annual Meeting
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that it will host an ePoster presentation and discussion of the company’s ALLEVIATE Phase 3 clinical trial of reproxalap in patients... 
From Business Wire News Releases
Aldeyra Therapeutics to Present at 2019 Cantor Global Healthcare Conference
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated... 
From Business Wire News Releases
Aldeyra Therapeutics Receives Fast Track Designation for ADX-2191 for the Prevention of Proliferative Vitreoretinopathy
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to ADX-2191 for the prevention of proliferative... 
From Business Wire News Releases
Aldeyra Therapeutics to Participate in Upcoming Investor Conferences
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated... 
From Business Wire News Releases
Aldeyra Therapeutics Announces Second Quarter 2019 Financial Results and Provides Corporate Update
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated... 
From Business Wire News Releases
Aileron Therapeutics Reports Second Quarter 2019 Financial Results
From GlobeNewswire News Releases
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second Quarter 2019 Financial Results and Corporate Update
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated... 
From Business Wire News Releases
Aldeyra Therapeutics Announces Results from the SOLACE Trial in Noninfectious Anterior Uveitis
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated... 
From Business Wire News Releases
Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Top-Line Results from the SOLACE Trial in Noninfectious Anterior Uveitis
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated... 
From Business Wire News Releases
Aileron Therapeutics Strengthens Board of Directors with Appointments of William T. McKee and Josef H. von Rickenbach
Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that William (“Bill”) T. McKee and... 
From GlobeNewswire News Releases
Aldeyra Therapeutics to Participate in the Jefferies 2019 Global Healthcare Conference
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated... 
From PR Newswire
Aldeyra Therapeutics Announces First Quarter 2019 Financial Results and Provides Corporate Update
- Reported Positive Results from Phase 3 ALLEVIATE Trial in Allergic Conjunctivitis 
From PR Newswire
Aldeyra Therapeutics to Report First Quarter 2019 Financial Results and Host Conference Call on Thursday, May 9, 2019
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated... 
From PR Newswire
Aldeyra Therapeutics Announces Last Patient Dosed in the SOLACE Phase 3 Clinical Trial
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated... 
From PR Newswire
Aldeyra Therapeutics Announces Presentation of Phase 2b Dry Eye Disease Results at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated... 
From PR Newswire
Recent Analysis Shows Flowserve, Pinnacle West Capital, Aldeyra Therapeutics, Donnelley Financial Solutions, NIC, and Enphase Energy Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Flowserve Corporation... 
From GlobeNewswire News Releases
Aldeyra Therapeutics Announces First Patient Enrolled in the RENEW Phase 3 Clinical Trial for Dry Eye Disease
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated... 
From PR Newswire
Medical Device Industry Revenues Should Outpace Healthcare Field
Financialnewsmedia.com News Commentary 
From PR Newswire
Medical Device Industry Revenues Should Outpace Healthcare Field
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Thinking about buying stock in Aldeyra Therapeutics, Bed Bath & Beyond Inc., Curis Inc., Cronos Group Inc., or Hunter Maritime Acquisition Corp.?
InvestorsObserver issues critical PriceWatch Alerts for ALDX, BBBY, CRIS, CRON, and HUNT. 
From PR Newswire
Aldeyra Therapeutics Announces Positive Top-Line Results from the Phase 3 ALLEVIATE Trial in Patients with Allergic Conjunctivitis
- Primary endpoint of ocular itch score area under the curve achieved for both tested reproxalap concentrations 
From PR Newswire
Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Top-Line Results from the Phase 3 ALLEVIATE Trial in Allergic Conjunctivitis
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated... 
From PR Newswire
Stoke Therapeutics Appoints Industry Veteran Stephen Tulipano as Chief Financial Officer
Stoke Therapeutics appointed Stephen J. Tulipano, CPA, MBA as chief financial officer. 
From Business Wire News Releases
Aldeyra Therapeutics Announces Year-End 2018 Financial Results
- Results from the ALLEVIATE Phase 3 Clinical Trial in Allergic Conjunctivitis Expected in Early 2019 
From PR Newswire
Aldeyra Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Friday, March 8, 2019
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated... 
From PR Newswire
Aldeyra Therapeutics Provides Update on Ophthalmic Programs at 2019 Research & Development Day
Phase 3 Results from ALLEVIATE Trial in Allergic Conjunctivitis Expected in Early 2019 
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.